<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03166410</url>
  </required_header>
  <id_info>
    <org_study_id>SVFOA-01</org_study_id>
    <nct_id>NCT03166410</nct_id>
  </id_info>
  <brief_title>Use of Autologous Adipose-Derived Stromal Vascular Fraction To Treat Osteoarthritis of Hip, Knee, Ankle, and Thumb Joints</brief_title>
  <official_title>Use of Autologous Adipose-Derived Stromal Vascular Fraction To Treat Osteoarthritis of Hip, Knee, Ankle, and Thumb Joints</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Plastic Surgery</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Plastic Surgery</source>
  <brief_summary>
    <textblock>
      This study will examine the safety and efficacy of autologous adipose-derived stromal&#xD;
      vascular fraction (SVF) cells for treatment of hip, knee and thumb osteoarthritis (OA);&#xD;
      monitoring adverse events and measuring pain, function and stiffness in the joints of&#xD;
      osteoarthritic subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <description>Subjects will be monitored for adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Change in Pain Scores at All Follow-up Visits</measure>
    <time_frame>3 months, 6 months, 1 year, 2 years</time_frame>
    <description>Pain scores will be collected at all visits</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Cell Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cell injection</intervention_name>
    <arm_group_label>Cell Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Grade II through Grade IV hip, knee, ankle osteoarthritis using Kellgren-Lawrence&#xD;
             grading scale (K-L Grade) as diagnosed using weight bearing X-ray, physician review,&#xD;
             and/or pre-op MRI&#xD;
&#xD;
          2. Stage II through IV carpometacarpal (CMC) osteoarthritis using Eaton-Little's staging&#xD;
             of CMC OA as diagnosed by X-ray and physical examination&#xD;
&#xD;
          3. Study Subjects must be willing to voluntarily give written Informed Consent to&#xD;
             participate in the study and sign the Health Insurance Portability and Accountability&#xD;
             Act (HIPAA) authorization before any study procedures are performed&#xD;
&#xD;
          4. Subjects with ASA grade I, II, or III&#xD;
&#xD;
          5. Males and females 25-85 years old&#xD;
&#xD;
          6. Subjects must have continued pain in their targeted/treatment joint despite&#xD;
             conservative therapies for at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects that are allergic to lidocaine, epinephrine or valium&#xD;
&#xD;
          2. Subjects with a history of bleeding disorders, anticoagulation therapy that cannot be&#xD;
             stopped as follows prior to injection; Thrombolytics and anti-platelet medication&#xD;
             including but not limited to Coumadin (warfarin) for 3 days, Plavix (clopidogrel) for&#xD;
             3 days, acetylsalicylic acid (ASA)/NSAIDs/fish oil supplements for 7 days, XeraltaÂ®&#xD;
             (rivaroxaban) for 24 hours&#xD;
&#xD;
          3. Subjects with systemic immunosuppressant use within six (6) weeks from screening and&#xD;
             subjects with HIV/viral hepatitis&#xD;
&#xD;
          4. Subjects with chondrocalcinosis, Paget's disease and Villonodular synovitis&#xD;
&#xD;
          5. Women that are pregnant or planning to become pregnant during the study&#xD;
&#xD;
          6. Subjects on long term use of oral steroids&#xD;
&#xD;
          7. History of any chemotherapy or radiation therapy on the targeted/treatment joint or&#xD;
             adipose harvest site&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Texas Plastic Surgery</last_name>
    <email>info@txps.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Texas Plastic Surgery</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 22, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2017</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas Plastic Surgery</investigator_affiliation>
    <investigator_full_name>Jaime R. Garza, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

